绿谷制药副总经理独家回应：“九期一”相关岗位已停工停产，企业一直在与监管机构积极沟通

Core Viewpoint - The Chinese innovative drug "Jiuqi Yi," known for its development as an Alzheimer's treatment, is facing production suspension due to the expiration of its drug registration certificate and failure to complete renewal approval on time [1][2]. Group 1: Company Situation - Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. announced that as of May 30, 2025, relevant positions for "Jiuqi Yi" have been suspended [1]. - The company has been actively communicating with regulatory authorities and participated in expert review meetings in March and April of this year [1]. - The company has accumulated significant research data and patient feedback, indicating a strong demand for the drug despite its current challenges [1]. Group 2: Production Facilities - The production base in Qingpu is still operational but primarily focuses on the production of other products, with the production line for "Jiuqi Yi" already suspended [2]. - The investment in the Shanghai Pudong production base totals 1.227 billion yuan, which was expected to be completed by the end of 2024, but has not been utilized since its construction [2]. - The lack of operation at the Pudong facility is attributed to the expiration of "Jiuqi Yi's" registration certificate and the company's current financial difficulties [2].